Turkey Neurology Clinical Trials Market Report 2022 to 2030

Turkey Neurology Clinical Trials Market Analysis

$ 3999

The Turkey Neurology Clinical Trials market is projected to grow from $41.8 Mn in 2022 to $66.7 Mn by 2030, registering a CAGR of 6% during the forecast period of 2022 - 2030. The market will be driven by the rising frequency of neurological illnesses such as Alzheimer's, Parkinson's, and stroke and rising investment in research facilities. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Novartis AG & Abdi İbrahim.

ID: IN10TRCT005 CATEGORY: Clinical Trials GEOGRAPHY: Turkey AUTHOR: Vidhi Upadhyay

Buy Now

Turkey Neurology Clinical Trials Market Executive Summary

The Turkey Neurology Clinical Trials market is projected to grow from $41.8 Mn in 2022 to $66.7 Mn by 2030, registering a CAGR of 6% during the forecast period of 2022 - 2030. According to data provided by clinicaltrials.gov, 903 clinical studies were launched in Türkiye between September 1, 2021, and September 1, 2022. Neurology has the highest proportion (105), followed by oncology (95) and orthopaedics (71). Alzheimer's and dementia fatalities in Turkey reached 17,308 in 2020, accounting for 4.45% of total deaths, according to the most recent WHO statistics. Turkey ranks 69 in the world with an age-adjusted death rate of 19.07 per 100,000 inhabitants. In Turkey, around 81,500 new acute ischemic strokes (AIS) were reported in 2019. IS was responsible for 65.1% of all strokes. 14.1% of those with IS were under the age of 50, 55.7% were under the age of 70, and 54.3% were women.

In recent years, the area of neurology clinical trials in Turkey has grown substantially. Turkey has become an increasingly desirable site for clinical trials, especially those in the area of neurology. The Turkish government has also developed measures to assist clinical research, such as attempts to enhance R&D funding and improve regulatory procedures. This has made it simpler for researchers in the nation to conduct clinical trials and has encouraged more industrial partners to participate in research initiatives. Many studies are underway, including those for the treatment of Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy, including stroke by healthcare facilities such as Istanbul University, Istanbul Medical Faculty, Ankara University, Faculty of Medicine, Acıbadem Healthcare Group, Koç University Hospital & Istanbul Florence Nightingale Hospital.

Turkey Neurology Clinical Trials Market

Market Dynamics

Market Growth Drivers

The country's rising investment in research facilities and resources is one of the primary factors. Turkish medical institutes and research institutions are drawing renowned researchers from all over the globe, and they are outfitted with cutting-edge equipment and technology to facilitate innovative clinical trials. Another major driver is Turkey's huge and diversified patient population, which is especially useful for clinical trials requiring a high number of participants or targeting certain communities. Moreover, due to its geographical position, Turkey is a good place for clinical trials involving patients from Europe, Asia, and the Middle East. The Turkish government has also developed measures to assist clinical research, such as attempts to enhance R&D funding and improve regulatory procedures. This has made it simpler for researchers in the nation to conduct clinical trials and has encouraged more industrial partners to participate in research initiatives.

Market Restraints

One of the most significant issues is a shortage of qualified clinical research workers, which may cause delays in trial execution and data processing. Also, increased patient knowledge and education regarding clinical trials are required, as well as more public-private collaborations to aid in the development of novel treatments and cures. Researchers may have limited access to funding for clinical investigations, limiting market development. Such factors may slow down the growth of the Neurology clinical trials market in Turkey.

Competitive Landscape

Key Players

Pfizer Inc.
Novartis AG
Sanofi
AstraZeneca
Abdi İbrahim (TUR)
Deva Holding A.S. (TUR)
Mustafa Nevzat (TUR)

Healthcare Policies and Regulatory Landscape

The Turkish Medicines and Medical Devices Agency, or TMMDA, is the primary regulatory organisation engaged in clinical trials. The agency's duty is to monitor and analyse human medicine clinical trials to ensure that they are safe and in accordance with international standards and guidelines. The research must also be approved by the ethics committee. A single ethics committee from a participating location is enough to approve the whole trial. This kind of ethics committee serves as a central ethics committee, approving research designs that adhere to sound clinical practises and suitable ethical norms.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Neurology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.